Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | ARHGDIA | P52565 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5416884 | 0.82 | ROCK2 (0.40) | S1PR1ROCK2ROCK1ARHGDIASLC6A2 | |
| SCHEMBL5404335 | 0.74 | RXRA (0.43) | — | |
| SCHEMBL5404336 | 0.72 | ROCK2 (0.70) | ROCK2ROCK1ARHGDIA | |
| Hydrochloric Acid SCHEMBL5404775 | 0.72 | ROCK2 (0.69) | ROCK2ROCK1ARHGDIA | |
| SCHEMBL17858292 | 0.65 | RORC (0.48) | S1PR1ROCK2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17858293 | 0.64 | RORC (0.47) | S1PR1ROCK2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5412656 | 0.63 | ROCK2 (0.73) | ROCK2ROCK1ARHGDIA | |
| SCHEMBL12339948 | 0.63 | S1PR1 (0.54) | S1PR1ROCK2ROCK1SLC6A2SLC6A4 | |
| SCHEMBL5412554 | 0.62 | POLB (0.50) | S1PR1ROCK2ROCK1SLC6A2SLC6A4 | |
| SCHEMBL4572171 | 0.62 | S1PR1 (0.50) | S1PR1ROCK2ROCK1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | S1PR1 209/4885ROCK2 2/4885ROCK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.